Phase 1 Dermal Safety Study of XF-73
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2019
At a glance
- Drugs Exeporfinium chloride (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions
- 28 Jan 2019 Results published in a Destiny pharma media release.
- 13 Apr 2018 New trial record
- 12 Apr 2018 According to a Destiny Pharma media release, first subject has been enrolled in this study.